Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... Critical Path Immunology created to discover and develop ... for immune system-related diseases -, SAN FRANCISCO, March 31 ... with Beckman Coulter, Inc. to,establish a Center for Critical Path ... disease. This facility, which will be managed by,ITI and located ...
... (PHPG) today reported its consolidated, audited, financial,results for its ... in fiscal year 2007 were a record at $15,100,000 ... the year was our,highest ever at $17,802,000 as was ... 2006, respectively., Pre-tax income for the year was ...
... 31 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) ... and distribution partner in Japan, has,received approval for ... Ministry of Health, Labour and Welfare,(MHLW) for the ... "We are proud to work with AnGes ...
Cached Biology Technology:The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 2The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 3Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 2Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 3Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 4Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 5Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 6Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 7Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 8Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 9Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4
(Date:4/23/2014)... Some manufacturers are turning away from using triclosan as ... over health concerns. And now scientists are reporting new ... published in the ACS journal Chemical Research in ... commercial substance called octylphenol, promoted the growth of human ... tumors in mice. , Kyung-Chul Choi and colleagues note ...
(Date:4/23/2014)... Exeter researcher has shed light on how an estimated ... remote outback have become reviled as pests and culled ... Environment and Sustainability Institute at the University of Exeter,s ... Australia, from their historic role helping to create the ... "invader." , The deserts of the Australian outback are ...
(Date:4/23/2014)... think one can argue that if we were to follow ... that we canthen we can solve the climate problem without ... foremost climate researchers, in the current issue of Bulletin ... take significant action on climate change now makes it more ... problem, Wigley explains in an exclusive Bulletin interview. ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2
... Kam Tang of the Virginia Institute of Marine Science ... play an important role in carrying hitchhiking bacteria to ... "Bacteria dispersal by hitchhiking on zooplankton," appeared in the ... National Academy of Sciences . It was co-authored by ...
... variant which increases susceptibility to tuberculosis (TB) in African ... (GWA) study. This is the first novel disease variant ... demonstrates that such studies are viable in African populations, ... Over the past few years, GWA studies, such as ...
... Joseph Nadeau, PhD, of Case Western Reserve University School ... Health (NIH) Director,s Pioneer Award. One of ... will investigate transgenerational genetic effects, where the biological features ... to depend as much on the genetics of ancestral ...
Cached Biology News:Study shows that hitchhiking bacteria can go against the flow 2Study shows that hitchhiking bacteria can go against the flow 3Genome study identifies genetic variant linked to TB susceptibility in Africans 2Genome study identifies genetic variant linked to TB susceptibility in Africans 3Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2
... BioGenex Super Sensitive Polymer-HRP ... a novel product based ... polymeric technology. This system ... to noise ratio and ...
... unit is an inexpensive personal or mini thermal ... process. Lightweight, with a small footprint, it can ... the researcher's desk. , The Gene Cycler thermal ... not have access to a large laboratory thermal ...
... Leu-CMK FLISP Assay with SR-101 ... Em=620 nm) • Accurately measure serine ... or permeabilization • B-Bridge's FLISP Kits ... serine proteases (FLISPs) to measure chymotrypsin-like ...
... He biolistic system enables 7-10 times more cells ... fits into the shocking chamber of the PDS-1000 ... wave over 7 microcarriers. By uniformly spreading the ... area, the system maximizes the number of cells ...
Biology Products: